Clinical Trials

A phase 3, multicenter, double blind, randomized, placebo-controlled study of ivosidenib in subjects ≥ 18 years of age with unresectable or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 prior systemic treatment regimen

Link : TBD
Status : PENDING
Population : Chondrosarcoma
Description : Ivosidenib vs. placebo
PI : A. Razak
Centers Opened : TBD
Phase : III
IIST/Pharma : Pharma